<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="71794">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171104</url>
  </required_header>
  <id_info>
    <org_study_id>2013LS104</org_study_id>
    <nct_id>NCT02171104</nct_id>
  </id_info>
  <brief_title>MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis</brief_title>
  <official_title>MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-institution, phase II study is designed to test the ability to achieve donor
      hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM)
      using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug
      monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe
      osteopetrosis (OP).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of subjects who achieve high-level donor hematopoietic engraftment (defined as neutrophil recovery by Day +42 post-transplant and ≥ 80% donor cells on the myeloid fraction of peripheral blood at Day +100 post-transplant)</measure>
    <time_frame>neutrophil recovery by Day +42 post-transplant and ≥ 80% donor cells on the myeloid fraction of peripheral blood at Day +100 post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of subjects who develop graft-versus-host disease</measure>
    <time_frame>by Day +100 post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of subjects who die from transplant complications</measure>
    <time_frame>Day +100 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of regimen-related toxicity (such as infection, acute renal failure, respiratory failure, cardiac failure, and veno-occlusive disease)</measure>
    <time_frame>Day +100 post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of radiographic, physiologic, neuro-psychologic, and/or biochemical changes</measure>
    <time_frame>at 6 months, 1 year and yearly for a total of 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mucopolysaccharidosis Disorders</condition>
  <condition>Hurler Syndrome</condition>
  <condition>Hunter Syndrome</condition>
  <condition>Maroteaux Lamy Syndrome</condition>
  <condition>Sly Syndrome</condition>
  <condition>Alpha-Mannosidosis</condition>
  <condition>Fucosidosis</condition>
  <condition>Aspartylglucosaminuria</condition>
  <condition>Glycoprotein Metabolic Disorders</condition>
  <condition>Sphingolipidoses</condition>
  <condition>Recessive Leukodystrophies</condition>
  <condition>Globoid Cell Leukodystrophy</condition>
  <condition>Metachromatic Leukodystrophy</condition>
  <condition>Niemann-Pick B</condition>
  <condition>Niemann-Pick C Subtype 2</condition>
  <condition>Sphingomyelin Deficiency</condition>
  <condition>Peroxisomal Disorders</condition>
  <condition>Adrenoleukodystrophy With Cerebral Involvement</condition>
  <condition>Zellweger Syndrome</condition>
  <condition>Neonatal Adrenoleukodystrophy</condition>
  <condition>Infantile Refsum Disease</condition>
  <condition>Acyl-CoA Oxidase Deficiency</condition>
  <condition>D-Bifunctional Enzyme Deficiency</condition>
  <condition>Multifunctional Enzyme Deficiency</condition>
  <condition>Alpha-methylacyl-CoA Racmase Deficiency</condition>
  <condition>Mitochondrial Neurogastrointestingal Encephalopathy</condition>
  <condition>Severe Osteopetrosis</condition>
  <condition>Hereditary Leukoencephalopathy</condition>
  <condition>Inherited Metabolic Disorders</condition>
  <arm_group>
    <arm_group_label>Inherited Metabolic Disease (IMD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Osteopetrosis (OP) - Except Haplo-Identical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Osteopetrosis (OP) -Haplo-Identical ONLY</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem Cell Transplantation</intervention_name>
    <description>Infusion given on Day 0</description>
    <arm_group_label>Inherited Metabolic Disease (IMD)</arm_group_label>
    <arm_group_label>Severe Osteopetrosis (OP) - Except Haplo-Identical</arm_group_label>
    <arm_group_label>Severe Osteopetrosis (OP) -Haplo-Identical ONLY</arm_group_label>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMD Preparative Regimen</intervention_name>
    <description>Anti-thymocyte Globulin (ATG)
Fludarabine
Busulfan</description>
    <arm_group_label>Inherited Metabolic Disease (IMD)</arm_group_label>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osteopetrosis Only Preparative Regimen</intervention_name>
    <description>Anti-thymocyte Globulin (ATG)
Fludarabine
Busulfan
Thiotepa</description>
    <arm_group_label>Severe Osteopetrosis (OP) - Except Haplo-Identical</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osteopetrosis Haploidentical Only Preparative Regimen</intervention_name>
    <description>Rituximab
Alemtuzumab
Busulfan
Fludarabine</description>
    <arm_group_label>Severe Osteopetrosis (OP) -Haplo-Identical ONLY</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD SR-A (Standard-Risk, Regimen A)</intervention_name>
    <description>N-acetylcysteine start day +1 through day +28</description>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD SR-B (Standard-Risk, Regimen B)</intervention_name>
    <description>N-acetylcysteine start day +1through day +56</description>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD HR-D (High-Risk, Regimen C)</intervention_name>
    <description>N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100</description>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD HR-D (High-Risk, Regimen D)</intervention_name>
    <description>N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100</description>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  0 through 55 years of age

          -  Adequate graft available

          -  Adequate organ function

          -  Eligible Diseases:

               1. Mucopolysaccharidosis Disorders (&quot;IMD&quot;):

                    1. MPS IH (Hurler syndrome)

                    2. MPS II (Hunter syndrome) if the patient has no or minimal evidence of
                       symptomatic neurologic disease but is expected to have a neurologic
                       phenotype

                    3. MPS VI (Maroteaux-Lamy syndrome)

                    4. MPS VII (Sly syndrome)

               2. Glycoprotein Metabolic Disorders (&quot;IMD&quot;):

                    1. Alpha mannosidosis

                    2. Fucosidosis

                    3. Aspartylglucosaminuria

               3. Sphingolipidoses and Recessive Leukodystrophies (&quot;IMD&quot;):

                    1. Globoid cell leukodystrophy

                    2. Metachromatic leukodystrophy

                    3. Niemann-Pick B patients (sphingomyelin deficiency)

                    4. Niemann-Pick C subtype 2

               4. Peroxisomal Disorders (&quot;IMD&quot;):

                    1. Adrenoleukodystrophy with cerebral involvement

                    2. Zellweger syndrome

                    3. Neonatal Adrenoleukodystrophy

                    4. Infantile Refsum disease

                    5. Acyl-CoA-Oxidase Deficiency

                    6. D-Bifunctional enzyme deficiency

                    7. Multifunctional enzyme deficiency

                    8. Alpha-methylacyl-CoA Racmase Deficiency (AMACRD)

                    9. Mitochondrial Neurogastrointestingal Encephalopathy (MNGIE)

               5. Severe Osteopetrosis (OP)

               6. Hereditary Leukoencephalopathy with axonal spheroids (HDLS; CSF1R mutation)

               7. Other Inherited Metabolic Disorders (IMD): Patients will also be considered who
                  have other lifethreatening, rare lysosomal, peroxisomal or other similar
                  inherited disorders characterized by white matter disease or other neurologic
                  manifestations for which there is rationale that transplantation would be of
                  benefit, such as certain patients with Wolman's disease, GM1 gangliosidosis,
                  I-cell disease, Tay-Sachs disease, Sandhoff disease or others.

        Exclusion Criteria:

          -  Any patient who in the judgment of the University of Minnesota Inherited Metabolic
             and Storage Disease Group has disease that is not likely to benefit from allogeneic
             HSCT, based on its nature, severity or state of progression

          -  Prior myeloablative chemotherapy exposure within 4 months of the start of
             conditioning on this protocol

          -  Uncontrolled bacterial, fungal or viral infections including HIV

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Weston Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Nelson</last_name>
    <phone>612-273-2925</phone>
    <email>knelso62@fairview.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Nelson</last_name>
      <phone>612-273-2925</phone>
      <email>knelso62@fairview.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 22, 2017</lastchanged_date>
  <firstreceived_date>June 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allogeneic hematopoietic cell transplantation</keyword>
  <keyword>bone marrow transplantation</keyword>
  <keyword>IMD</keyword>
  <keyword>AMACRD</keyword>
  <keyword>MNGIE</keyword>
  <keyword>HDLS</keyword>
  <keyword>OP</keyword>
  <keyword>ALD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Adrenoleukodystrophy</mesh_term>
    <mesh_term>Osteopetrosis</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Mannosidase Deficiency Diseases</mesh_term>
    <mesh_term>alpha-Mannosidosis</mesh_term>
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
    <mesh_term>Leukoencephalopathies</mesh_term>
    <mesh_term>Leukodystrophy, Globoid Cell</mesh_term>
    <mesh_term>Sphingolipidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
    <mesh_term>Mucopolysaccharidosis VII</mesh_term>
    <mesh_term>Fucosidosis</mesh_term>
    <mesh_term>Peroxisomal Disorders</mesh_term>
    <mesh_term>Refsum Disease</mesh_term>
    <mesh_term>Refsum Disease, Infantile</mesh_term>
    <mesh_term>Zellweger Syndrome</mesh_term>
    <mesh_term>Aspartylglucosaminuria</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
    <mesh_term>Gonadal Dysgenesis, 46,XX</mesh_term>
    <mesh_term>Intestinal Pseudo-Obstruction</mesh_term>
    <mesh_term>Mitochondrial Encephalomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
